后天抵抗
依托泊苷
癌症研究
交叉电阻
生物
拓扑替康
奥拉帕尼
抗药性
肿瘤科
医学
DNA
遗传学
化疗
聚ADP核糖聚合酶
聚合酶
作者
Shreoshi Pal Choudhuri,Luc Girard,Jun Yi Stanley Lim,Jillian F. Wise,Braeden Freitas,Di Yang,Edmond Wong,Seth Hamilton,Victor D. Chien,Collin Gilbreath,Jun Zhong,Sarah Phat,David T. Myers,Camilla L. Christensen,Marcello Stanzione,Kwok‐Kin Wong,Anna F. Farago,Catherine B. Meador,Nicholas J. Dyson,Michael S. Lawrence
标识
DOI:10.1101/2023.06.23.546278
摘要
SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population of PDX models to discover that amplifications of MYC paralogs on ecDNA are recurrent drivers of acquired cross-resistance in SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI